Whereas cell-intrinsic therapy resistance is typically attributed to a single mutational or non-mutational mechanism, our studies with experimental models of ALK+ NSCLC revealed a more complex scenario of multifactorial resistance (5). This evidence concerns the gene ALK and non-small cell lung carcinoma.